BCTX Company Profile and Key Details

BCTX has shown weak momentum, losing -42.8% over the past week and -63.12% over the past quarter, though year-to-date performance is down -38.54%. Short-term trend indicators are bullishly aligned (SMA20 -2.67%, SMA50 -30.75%, SMA200 -69.58%). The stock’s 14-day RSI is 40.3 (neutral), while the ATR of 0.41 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -95.93% below its high and over 11.11% above its low. Average 10-day trading volume of 260.64 thousand shares is below the 3-month average of 472.03 thousand, indicating normal recent market interest.

BriaCell Therapeutics Corp. has 1.88 million shares outstanding. The public float is 1.56 million shares, elevated short interest at 5.29% of float. This equals 92.14 thousand shares. The short ratio is 1.3 days. Institutional investors hold 9.91% of the float. Insiders own 2.55%. Lustig Marc holds 902.94 thousand shares, Bondarenko Jamieson has 169.86 thousand shares and Williams William V. has 29.80 thousand shares.

BriaCell Therapeutics Corp. generated EPS of -$48.35 over the past year. Five-year average earnings growth is 39.57%. The latest quarter delivered EPS of -$10.49. The next quarter is forecast at $nan. Next year's EPS is expected at $8.30. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $40.00 to $40.00. The high target offers 949.87% upside. The low target suggests 949.87% downside. The mean target is $40.00. This offers 949.87% upside. BriaCell Therapeutics Corp. earnings surprise history is frequent misses against expectations. The quarter that ended October 27, 2025, missed forecasts by -13.38%. The prior quarter beat by -6.82%. Over the last six quarters, Apple has recorded several small beats. These include -120.0% in June 14, 2024.

BriaCell Therapeutics Corp. (NASDAQ:BCTX) closed at $4.34 USD, gaining $0.53 (13.91%) from the previous close of $3.81. The stock is currently mid-range between its 52-week high and low $3.60 and $98.20. With a market capitalization of about $8.18 million, BriaCell Therapeutics Corp. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.80). Key stats such as the average daily volume over the past year has been around 468.30 thousand shares, in line with its 52-week average. Headquartered in West Vancouver, BC, BriaCell Therapeutics Corp. operates in the Healthcare sector and the Biotechnology industry. Led by CEO William V. Williams, the company employs approximately 16 people and listed since March 14, 2012. BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer.

BriaCell Therapeutics Corp. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $5.64. This means the shares are trading below this model’s fair value.

BriaCell Therapeutics Corp. (NASDAQ:BCTX) shares are down -38.54% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows BriaCell Therapeutics Corp. trading at a premium to the broader market with a P/E of -0.31. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $22.27, suggesting 484.51% upside. Our AI forecast model points to short-term weakness (-6.82% over two weeks), a medium-term rise (272.18% over three months), and a longer-term loss (-97.9% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that BriaCell Therapeutics Corp. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -6.82%, with price expected at $3.55 by March 24, 2026, within a range of $3.35 to $3.74 3-Month Outlook: Projected rise of 272.18%, reaching $14.18 by June 08, 2026, with a range of $11.57 to $17.10. 1-Year Outlook: Projected loss of -97.9%, with price at $0.08 by March 10, 2027, within a range of $0.00 to $8.50.

BriaCell Therapeutics Corp. trades at a P/E ratio of -0.31, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.39 suggesting the stock is closer to book value. The P/FCF stands at -0.22, also above market averages.